Fierce Biotech News & Reports

ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed

Incyte has unveiled phase 1 data suggesting its KRAS G12D inhibitor could rival RevMed’s contender in the increasingly competitive pancreatic cancer space.

James Waldron Oct 26, 2026 9:45am

ESMO: J&J's RIPTAC is ‘best data we’ve seen’ for prostate cancer

Oct 25, 2026 9:45am

ESMO: AZ exec insists ph. 3 ADC data ‘robust’ despite PFS miss

Oct 25, 2026 11:30am

ESMO: Merck exec unruffled by ‘unfortunate’ cancer vax data leak

Oct 24, 2026 6:24am

ESMO: Roche touts ‘convincing’ KRAS data after phase 3 win

Oct 25, 2026 11:30am

Boehringer, Microsoft explore digital twins for clinical trials

Oct 26, 2026 2:49pm

More News

Anthropic details drug R&D ambitions, risks in IPO filing

Oct 26, 2026 2:00pm

Lycia leaps onto Nasdaq with $318M IPO as Windward eyes debut

Oct 26, 2026 10:00am

BioNTech sees limited ADC benefit as ph. 3 shows modest efficacy

Oct 26, 2026 8:39am

ESMO: Genmab's ph. 3 win for Rina-S, fresh data on Merus prize

Oct 26, 2026 7:00am

See more stories